Navigation Links
Alexza Receives Complete Response Letter for Adasuve™ NDA
Date:5/3/2012

n risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the potential of the Company to adequately address the issues in the recently received CRL, the timing of the Company's response to the CRL, the timing and prospects for regulatory approval to market ADASUVE in the U.S., the timing and prospects for regulatory approval to market ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries and the adequacy of the Company's capital to support the Company's operations, the Company's ability to raise additional funds and the potential terms of such potential financings. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2011 and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014  The National Association of Drug Diversion ... by Kentucky,s real-time, stop-sale ... National Precursor Log Exchange (NPLEx) system automatically blocks ... and helps flag meth offenders for law enforcement. ... NPLEx "watch lists" that notify them via email ...
(Date:10/25/2014)... 2014 Burzynski Research Institute, Inc. (BRI) announced ... has given the company permission to conduct an open-label ... 3 months of age with a diffuse intrinsic brainstem ... of five treatment groups based on their age and ... DIPG. The primary study endpoint is a decrease in ...
(Date:10/22/2014)... N.J. , Oct. 22, 2014  Rescheduling ... major transformation in the pain market, according to ... Insights, Inc., a firm providing market research and ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... scheduling change for hydrocodone combination products from Schedule ...
Breaking Medicine Technology:Kentucky's NPLEx Technology Making Significant Progress 2Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3
... will be presented at the American College of,Cardiology's ... 2007 /PRNewswire-FirstCall/ -- CV,Therapeutics, Inc. announced today that ... study of ranolazine shows there was no,adverse trend ... study did not meet the primary efficacy endpoint. ...
... in Intestinal Adenomas Suggesting,Possible Beneficial Mediation in the ... 07, 2007 /PRNewswire/ -- NutraCea,announced today the results ... bran,on the number of intestinal adenomas in cancerous ... of the prestigious British,Journal of Cancer conducted at ...
Cached Medicine Technology:CV Therapeutics Announces Topline MERLIN TIMI-36 Results 2CV Therapeutics Announces Topline MERLIN TIMI-36 Results 3British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 2British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 3British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 4
(Date:10/25/2014)... The proposed consolidation of all federally-filed ... December, when the U.S. Judicial Panel on Multidistrict Litigation ... Hearing Session Order issued by the Panel on October ... on December 4, 2014, in Charleston, South Carolina. The ... Xarelto Products Liability Litigation, No. 2592) , “Our Firm ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 TASC ... medical and other benefits account management services, announces ... help employers save on taxes, reduce administrative workload, ... provide tax savings and the efficient handling of ... the Suite that best meets their goals and ...
(Date:10/25/2014)... 2014 The federal judge overseeing ... ) filed against Boston Scientific Corp. in the ... Southern District of West Virginia has denied a ... in a group of cases filed on behalf ... October 21st, U.S. District Judge Joseph R. Goodwin ...
(Date:10/25/2014)... Not getting the right amount of sleep might raise ... Those who sleep less or more than the ... more prone to developing the chronic condition, which causes ... concluded that duration and quality of sleep are key ... diseases. "Both short and long durations of sleep ...
(Date:10/25/2014)... -- October,s shorter, darker days can trigger a type ... an expert. People affected by seasonal affective ... motivation and even have trouble getting out of bed. ... Dr. Angelos Halaris, a professor in the department of ... School of Medicine. "Seasonal affective disorder should not ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 3Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Dark Days Here for Folks With Seasonal Depression 2
... take medication to manage their symptoms of attention deficit ... ADHD - partially because the process can be so ... to simplify things with expert explanations of popular ADD ... YORK, May 27 ADDitude magazine, the ...
... 27, 2009 The Translational Genomics Research Institute (TGen) ... million to research pancreatic cancer, Stand Up to Cancer ... Physician-In-Chief, and Dr. Craig B. Thompson, Director of the ... pancreatic cancer "Dream Team, which will lead a three-year ...
... May 27 PRA International, a leading Clinical ... Center in its Sao Paulo, Brazil office. Drug Safety ... Risk Management unit. They are staffed with drug safety ... Adverse Drug Reaction management. Furthermore, our drug safety ...
... The Providence Service Corporation (Nasdaq: PRSC ... the proxy statement filed last week by the Avalon ... that the Avalon Group,s proxy statement contains numerous false ... necessary for it to correct the public record with ...
... include worries about family,s reaction, study finds , , WEDNESDAY, ... reaction to their depression is a major reason why ... In the study, which included 368 teens and one ... teens had been diagnosed with depression. The teens and ...
... CLINTON, N.J., May 27 The Sage Group, a ... that HemispherX Biopharma has expanded the mandate for The ... partnering efforts related to Ampligen (an experimental immunotherapeutic) for ... to Ampligen,s use to increase the effectiveness of preventative ...
Cached Medicine News:Health News:ADHD Treatment Guide: How to Safely, Effectively Use Medications and Non-Drug Therapies to Treat Attention Deficit Disorder 2Health News:$18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research 2Health News:$18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research 3Health News:$18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research 4Health News:$18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research 5Health News:PRA International Opens Additional Drug Safety Center in Sao Paulo, Brazil 2Health News:PRA International Opens Additional Drug Safety Center in Sao Paulo, Brazil 3Health News:Providence Service Corporation Rebuts False and Misleading Statements Contained in Proxy Statement Filed by the Avalon Group 2Health News:Providence Service Corporation Rebuts False and Misleading Statements Contained in Proxy Statement Filed by the Avalon Group 3Health News:Stigma Keeps Teens From Depression Treatment 2Health News:The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate 2Health News:The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate 3Health News:The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate 4
... The Cryostage freezing stage is a refrigerated ... object holder, primarily for use with the 8000 ... other sledge microtomes. ,The refrigerated stage gives a ... the surface is ridged to provide good adhesion ...
... work, it is necessary to cool a specimen ... be fitted to most microtomes and will permit ... depending on conditions. The equipment consists of a ... stage is best suited for operation with a ...
... Freezing Stages fit easily onto most microtomes. ... need only the AC supply and a trickle ... starts immediately and can be maintained indefinitely. ... temperatures can be set for different kinds of ...
... MNL 4404 & 4405 series Freezing Stages ... devices have no moving parts and need only ... water for operation. Freezing starts immediately ... is adjustable so that optimum cutting temperatures can ...
Medicine Products: